Compare Hershey Co (HSY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs TransMedics Group Inc — how do they compare? Hershey Co trades at $162.36 (market cap $32.66B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Hershey Co is far larger — about 11.9× TransMedics Group Inc's market cap, and Hershey Co pays a 3.57% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and TransMedics Group Inc for 24 Days on average.
| HSY | TMDX | |
|---|---|---|
Market Cap | $32.66B | $2.74B |
Volume | 1,578,237 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $150.42 |
52-Week Low | $157.61 | $61.99 |
Typical Hold Time | 135 Days | 24 Days |
Enterprise Value | $37.79B | $3.13B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.74, up 1.5% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats (3 of last 4 quarters) with Q3 2026 results pending. Revenue grew to $11.69B in 2025, though net margin compressed to 7.55% from 19.82% in 2024. Analyst consensus targets $204.62 (25.7% upside) with 65.7% hold ratings. Recent news highlights dividend resumption and international leadership changes.
HSY presents a mixed outlook: valuation appears reasonable (P/E 22.2) with strong brand positioning, but faces margin pressure from commodity costs. The technical bearish trend near key support at $161 suggests near-term caution. Long-term investors may find value given dividend growth resumption and consistent market share, though cocoa price volatility remains a key risk.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
